These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33000285)

  • 21. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
    PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
    Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.
    Sinha MD; Turner C; Booth CJ; Waller S; Rasmussen P; Goldsmith DJ; Simpson JM
    Pediatr Nephrol; 2015 Oct; 30(10):1843-52. PubMed ID: 25975437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
    Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
    Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.
    Isakova T; Xie H; Barchi-Chung A; Vargas G; Sowden N; Houston J; Wahl P; Lundquist A; Epstein M; Smith K; Contreras G; Ortega L; Lenz O; Briones P; Egbert P; Ikizler TA; Jueppner H; Wolf M
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2688-95. PubMed ID: 21903990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T
    Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor 23 is a predictor of aortic artery calcification in maintenance hemodialysis patients.
    Chen Z; Chen X; Xie J; Ma X; Zhong F; Hou L; Ling H; Li X; Ren H; Chen N
    Ren Fail; 2013; 35(5):660-6. PubMed ID: 23581403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study.
    Cernaro V; Lucisano S; Canale V; Bruzzese A; Caccamo D; Costantino G; Buemi M; Santoro D
    J Nephrol; 2018 Jun; 31(3):429-433. PubMed ID: 28401422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
    Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
    Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between residual renal function and serum fibroblast growth factor 23 in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Taniguchi M; Yoshida H; Tokumoto M; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Ther Apher Dial; 2014 Oct; 18(5):383-90. PubMed ID: 24674095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.
    di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C
    PLoS One; 2015; 10(7):e0133580. PubMed ID: 26193703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Circulating bone turnover markers and their relationships in hemodialysis patients with vitamin D deficiency].
    Kulicki P; Żebrowski P; Sokalski A; Klatko W; Birecka M; Mieczkowski M; Niemczyk S; Małyszko J; Matuszkiewicz-Rowińska J
    Wiad Lek; 2019; 72(11 cz 2):2202-2209. PubMed ID: 31860837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis.
    Bi S; Liang Y; Cheng L; Wang Y; Wang T; Han Q; Zhang A
    Int Urol Nephrol; 2017 Sep; 49(9):1653-1659. PubMed ID: 28455658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.
    Shimada T; Urakawa I; Isakova T; Yamazaki Y; Epstein M; Wesseling-Perry K; Wolf M; Salusky IB; Jüppner H
    J Clin Endocrinol Metab; 2010 Feb; 95(2):578-85. PubMed ID: 19965919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.